• Alchemy IoT

  Led · Seed · Dec 2017

  Alchemy IoT provides Clarity, a cloud-based, no-code IoT application that creates digital twins of industrial assets and applies unsupervised machine learning to analyze performance. Clarity lets teams visualize asset information in graphical dashboards, connect asset data feeds to the cloud, and take proactive action to improve fleet and machinery productivity. The product targets fleet management, plant maintenance and manufacturing performance use cases. The company emphasizes a no-code approach to lower the technical and data‑science barriers for small- and mid-sized industrial customers. Led by CEO Victor Perez, Alchemy IoT will focus on enabling those customers to deploy IoT solutions without large engineering or data-science teams. Financially, the company raised $4M in seed funding.

• Vertos Medical

  Participated · Equity · Jun 2017

  Vertos Medical develops minimally invasive treatments for lumbar spinal stenosis, centered on its mild Procedure. The company offers a procedure that targets chronic low back pain and has treated more than 70,000 patients in the United States. Demand for the mild Procedure is increasing significantly. Vertos plans to use new capital to expand patient access and to support research and development aimed at advancing care for chronic low back pain. The financing strengthens its commercial expansion efforts and capacity to scale adoption. Vertos positions itself to make a meaningful impact on mobility and quality of life for older adults with LSS. Vertos Medical Inc. is a medical device company committed to developing innovative, minimally invasive treatments for lumbar spinal stenosis (LSS). Its proprietary mild® technology is described as a safe, minimally invasive outpatient procedure that restores space in the spinal canal through an incision smaller than the size of a baby aspirin. The company emphasizes outpatient, low‑invasiveness approaches for LSS treatment. The announcement notes a significant equity investment from Partner Ventures. No financing size, operating metrics, or additional financial details were provided in the article. The company website is referenced for more information. Vertos Medical, based in Aliso Viejo, California, develops innovative, minimally invasive treatments for lumbar spinal stenosis (LSS). Its core product is the mild® procedure, an outpatient, fluoroscopically guided therapeutic LSS treatment that requires no general anesthesia, no implants, and no stitches. The mild procedure restores space in the spinal canal by removing hypertrophic ligamentum flavum through a 5.1-mm treatment portal using specialized devices. The company intends to use the financing to expand commercialization of mild® and to support physician training and education to broaden patient access. The company is led by President and CEO Eric Wichems. Vertos Medical recently closed a financing to support these commercial and training initiatives. Vertos Medical, based in Aliso Viejo, CA, develops and commercializes mild, a minimally invasive outpatient procedure for lumbar spinal stenosis (LSS). mild is performed through an incision the size of a baby aspirin, requires no general anesthesia, no implants and no stitches, and its efficacy and safety have been demonstrated in 11 clinical studies and more than 16 peer‑reviewed articles. Since receiving FDA 510(k) clearance in 2008, more than 15,000 people in the U.S. have been treated with mild, and the procedure has a reported 81% positive‑response rate. Vertos positions mild as a low‑cost, durable alternative to other LSS treatments, aiming to reduce complications and recovery time compared with open back surgery. The company announced it has closed nearly $23 million in a Series E financing led by Pitango Venture Capital to support commercial growth. Proceeds will be used for U.S. commercial expansion and to launch mild in European markets. Vertos Medical develops the mild procedure, a proprietary minimally invasive treatment for lumbar spinal stenosis (LSS). The mild procedure targets a large underserved group: patients who no longer respond to medical management but are not yet candidates for traditional invasive surgeries. The company is Aliso Viejo, CA-based and led by president and chief executive officer James M. Corbett. Vertos will use the Series D proceeds to continue U.S. commercialization of its mild technology. Company leadership described the financing as an important milestone and recognition of the market potential of the mild procedure.

• Sinopsys Surgical

  Participated · Equity · Jul 2012

  Sinopsys Surgical is developing a technique and hollow silicone lacrimal stent that reroutes the tear duct to the sinuses to allow topical delivery of antibiotics into the paranasal cavities. The procedure is described as an outpatient, roughly five-minute duct rerouting and stent implant. By delivering eye drops directly into the sinus, the company aims to increase local antibiotic concentration for patients with chronic sinusitis refractory to other treatments. The firm estimates a target market of about 7 million patients for whom other treatments prove ineffective. Sinopsys operates in stealth from a single-page website and has disclosed details at industry forums. Financially, the company announced an $8.3 million equity funding round and previously—under the predecessor name DCS Surgical—won FDA 510(k) clearance for an initial indication. Sinopsys Surgical (also known as DCS Surgical Inc.) is a stealth medical‑device company developing minimally invasive surgical technology for the lacrimal system, which manages tear production and drainage. The company is building devices to treat blocked tear ducts and other lacrimal conditions. It competes with Quest Medical, FCI Ophthalmics and Sterimedix. Sinopsys is based in Boulder, Colorado, and is led by CEO Harry Ross, a former partner at Aweida Venture Partners. Financially, the company sold half of a $2.4 million equity offering, raising $1.2 million in the reported transaction. An SEC filing lists participating investors as directors from DFJ Mercury, High Country Venture and Aweida Venture Partners. The company remains in stealth as it advances its lacrimal surgery technology.

No current team members are available.